Latest & greatest articles for atrial fibrillation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on atrial fibrillation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on atrial fibrillation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for atrial fibrillation

121. Long-term bleeding risk prediction in 'real world' patients with atrial fibrillation: Comparison of the HAS-BLED and ABC-Bleeding risk scores. The Murcia Atrial Fibrillation Project

Long-term bleeding risk prediction in 'real world' patients with atrial fibrillation: Comparison of the HAS-BLED and ABC-Bleeding risk scores. The Murcia Atrial Fibrillation Project 28799620 2017 08 11 2017 08 11 0340-6245 117 10 2017 Aug 11 Thrombosis and haemostasis Thromb. Haemost. Long-term bleeding risk prediction in 'real world' patients with atrial fibrillation: Comparison of the HAS-BLED and ABC-Bleeding risk scores. The Murcia Atrial Fibrillation Project. 10.1160/TH17-07-0478 Risk (...) scores in patients with atrial fibrillation (AF) based on clinical factors alone generally have only modest predictive value for predicting high risk patients that sustain events. Biomarkers might be an attractive prognostic tool to improve bleeding risk prediction. The new ABC-Bleeding score performed better than HAS-BLED score in a clinical trial cohort but has not been externally validated. It was the aim of this study to compare the predictive performance of the ABC-Bleeding score compared to HAS

EvidenceUpdates2017

122. Comparison of the CHA2DS2-VASc, CHADS2, HAS-BLED, ORBIT, and ATRIA Risk Scores in Predicting Non-Vitamin K Antagonist Oral Anticoagulants-Associated Bleeding in Patients With Atrial Fibrillation

Comparison of the CHA2DS2-VASc, CHADS2, HAS-BLED, ORBIT, and ATRIA Risk Scores in Predicting Non-Vitamin K Antagonist Oral Anticoagulants-Associated Bleeding in Patients With Atrial Fibrillation 28844514 2017 08 28 2017 08 28 1879-1913 2017 Jul 31 The American journal of cardiology Am. J. Cardiol. Comparison of the CHA2DS2-VASc, CHADS2, HAS-BLED, ORBIT, and ATRIA Risk Scores in Predicting Non-Vitamin K Antagonist Oral Anticoagulants-Associated Bleeding in Patients With Atrial Fibrillation (...) . S0002-9149(17)31224-9 10.1016/j.amjcard.2017.07.051 The increasing adoption of non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation (AF) necessitates a reassessment of bleeding risk scores. Because known risk factors for bleeding are largely the same as for stroke, we hypothesize that stroke risk scores could also be used to identify patients with high bleeding risks. We aimed to compare the performance of 2 stroke risk scores (Congestive Heart

EvidenceUpdates2017

123. Assessment of Remote Heart Rhythm Sampling Using the AliveCor Heart Monitor to Screen for Atrial Fibrillation: The REHEARSE-AF Study

Assessment of Remote Heart Rhythm Sampling Using the AliveCor Heart Monitor to Screen for Atrial Fibrillation: The REHEARSE-AF Study 28851729 2017 08 30 2017 08 30 1524-4539 2017 Aug 28 Circulation Circulation Assessment of Remote Heart Rhythm Sampling Using the AliveCor Heart Monitor to Screen for Atrial Fibrillation: The REHEARSE-AF Study. CIRCULATIONAHA.117.030583 10.1161/CIRCULATIONAHA.117.030583 Background -Asymptomatic atrial fibrillation (AF) is increasingly common in the aging (...) population and implicated in many ischemic strokes. Earlier identification of AF with appropriate anticoagulation may decrease stroke morbidity and mortality. Methods -We conducted a randomized controlled trial of AF screening using an AliveCor Kardia monitor attached to a WiFi-enabled iPod to obtain ECGs (iECGs) in ambulatory patients. Patients ≥65 years of age with a CHADS-VASc score ≥2 free from AF were randomized to the iECG arm or routine care (RC). iECG participants acquired iECGs twice weekly over

EvidenceUpdates2017 Full Text: Link to full Text with Trip Pro

124. Bleeding-related hospital admissions and 30-day readmissions in patients with non-valvular atrial fibrillation treated with dabigatran versus warfarin

Bleeding-related hospital admissions and 30-day readmissions in patients with non-valvular atrial fibrillation treated with dabigatran versus warfarin 28748652 2017 07 27 2017 08 17 1538-7836 2017 Jul 27 Journal of thrombosis and haemostasis : JTH J. Thromb. Haemost. Bleeding-related hospital admissions and 30-day readmissions in patients with non-valvular atrial fibrillation treated with dabigatran versus warfarin. 10.1111/jth.13780 Essentials Bleeding is a common cause of hospital admission (...) . Compared with warfarin, dabigatran achieves a full anticoagulation effect more quickly following its initiation; hence it may lead to early-onset bleeds. Objectives To compare the incidence of bleeding-related hospital admissions and 30-day readmissions with dabigatran vs. warfarin in patients with non-valvular atrial fibrillation (NVAF). Methods This was a retrospective cohort study using a population-wide database managed by the Hong Kong Hospital Authority. Patients newly diagnosed with NVAF from

EvidenceUpdates2017

125. Lixiana (edoxaban) - for the prevention of embolism in patients with nonvalvular atrial fibrillation OR treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE.

Lixiana (edoxaban) - for the prevention of embolism in patients with nonvalvular atrial fibrillation OR treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE. Lixiana (edoxaban) × Insert searchphrase to search the website Insert searchphrase to search the website > > > Lixiana (edoxaban) Conclusion Lixiana (edoxaban) is the fourth Non-vitamin K Oral Anticoagulant (NOAC) in Denmark after Eliques (apixaban), Xarelto (rivaroxaban) and Pradaxa (...) (dabigatran). Lixiana is indicated for the prevention of embolism in patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE. For either indication, Lixiana is not inferior to warfarin when it comes to preventing embolism and has a statistically significantly lower occurrence of major bleeding. The lower risk of bleeding is particularly evident in comparisons

Danish Pharmacotherapy Reviews2017

126. The Correlation with New-Onset Atrial Fibrillation and Increased Cancer Risk

The Correlation with New-Onset Atrial Fibrillation and Increased Cancer Risk "The Correlation with New-Onset Atrial Fibrillation and Increased Cance" by Jessica Sclafani < > > > > Title Author Date of Graduation Summer 8-12-2017 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background : Atrial fibrillation (AF) is one of the most common heart arrhythmias world-wide with Americans >40 years old having a lifetime risk of 26% for men (...) and 23% for women. It is estimated that 2.3 million adults in the United States are currently diagnosed with AF with an expected increase to 5.6 million by the year 2050. AF is strongly associated with significant cardiovascular (CV) and cerebrovascular compilations such as heart failure, stroke and myocardial infarction, as well as non-CV causes of death including cancer. Previous investigative focus has been on incidence of AF post-cancer diagnosis or as sequela following cancer treatment

Pacific University EBM Capstone Project2017

127. Impact of creatinine clearance on outcomes in patients with non-valvular atrial fibrillation: a subanalysis of the J-RHYTHM Registry

Impact of creatinine clearance on outcomes in patients with non-valvular atrial fibrillation: a subanalysis of the J-RHYTHM Registry 28950373 2018 11 13 2058-1742 4 1 2018 01 01 European heart journal. Quality of care & clinical outcomes Eur Heart J Qual Care Clin Outcomes Impact of creatinine clearance on outcomes in patients with non-valvular atrial fibrillation: a subanalysis of the J-RHYTHM Registry. 59-68 10.1093/ehjqcco/qcx032 To clarify the influence of renal function on adverse outcomes (...) in patients with non-valvular atrial fibrillation (NVAF), a post hoc analysis of the J-RHYTHM Registry was performed. A consecutive series of outpatients with atrial fibrillation (AF) were enrolled from 158 institutions and followed for 2 years or until the occurrence of an event. Among 7406 patients with non-valvular AF, 6052 patients (69.8 ± 10.0 years, 71.2% men) with creatinine clearance (CrCl) value at baseline were divided into four groups according to CrCl level (<30, 30-49.9, 50-79.9, and ≥80 mL

European heart journal. Quality of care & clinical outcomes2017 Full Text: Link to full Text with Trip Pro

128. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.

Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. Background Triple antithrombotic therapy with warfarin plus two antiplatelet agents is the standard of care after percutaneous coronary intervention (PCI) for patients with atrial fibrillation, but this therapy is associated with a high risk of bleeding. Methods In this multicenter trial, we randomly assigned 2725 patients with atrial fibrillation who had undergone PCI to triple therapy with warfarin plus a P2Y12 (...) with 13.4% in the triple-therapy group (hazard ratio, 1.04; 95% CI, 0.84 to 1.29; P=0.005 for noninferiority). The rate of serious adverse events did not differ significantly among the groups. Conclusions Among patients with atrial fibrillation who had undergone PCI, the risk of bleeding was lower among those who received dual therapy with dabigatran and a P2Y12 inhibitor than among those who received triple therapy with warfarin, a P2Y12 inhibitor, and aspirin. Dual therapy was noninferior to triple

NEJM2017

129. A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial.

A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial. BACKGROUND: Oral anticoagulation is underused in patients with atrial fibrillation. We assessed the impact of a multifaceted educational intervention, versus usual care, on oral anticoagulant use in patients with atrial fibrillation. METHODS: This study was a two-arm, prospective, international, cluster-randomised, controlled trial. Patients (...) were included who had atrial fibrillation and an indication for oral anticoagulation. Clusters were randomised (1:1) to receive a quality improvement educational intervention (intervention group) or usual care (control group). Randomisation was carried out centrally, using the eClinicalOS electronic data capture system. The intervention involved education of providers and patients, with regular monitoring and feedback. The primary outcome was the change in the proportion of patients treated

Lancet2017

130. Association of a Family History of Atrial Fibrillation With Incidence and Outcomes of Atrial Fibrillation: A Population-Based Family Cohort Study

Association of a Family History of Atrial Fibrillation With Incidence and Outcomes of Atrial Fibrillation: A Population-Based Family Cohort Study 28678986 2018 11 13 2380-6591 2 8 2017 Aug 01 JAMA cardiology JAMA Cardiol Association of a Family History of Atrial Fibrillation With Incidence and Outcomes of Atrial Fibrillation: A Population-Based Family Cohort Study. 863-870 10.1001/jamacardio.2017.1855 The heritability of atrial fibrillation (AF), the contribution of genetic and environmental (...) factors, and the association of a family history of AF with prognosis are unclear. To measure genetic and environmental factors in the familial aggregation of AF and to estimate the association of a family history of AF with major adverse cardiovascular events (MACE). In this Taiwanese nationwide population-based study among more than 23 million people, a custom data set was obtained using the data of all patients having a diagnosis of AF recorded between January 1996 and December 2013 in the Taiwan

JAMA cardiology2017 Full Text: Link to full Text with Trip Pro

131. Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study

Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study 28614582 2018 11 13 2380-6591 2 8 2017 Aug 01 JAMA cardiology JAMA Cardiol Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study. 872-881 10.1001 (...) /jamacardio.2017.1883 The randomized clinical trials comparing nonvitamin K antagonist oral anticoagulants (NOACs) vs warfarin largely focused on recruiting high-risk patients with atrial fibrillation with more than 2 stroke risk factors, with only the trials testing dabigatran or apixaban including few patients with 1 stroke risk factor. Despite this, regulatory approvals of all NOACs have been based on stroke prevention for patients with atrial fibrillation with 1 or more stroke risk factors. To compare

JAMA cardiology2017 Full Text: Link to full Text with Trip Pro

132. Influence of renal function on anticoagulation control in patients with non-valvular atrial fibrillation taking vitamin K antagonists

Influence of renal function on anticoagulation control in patients with non-valvular atrial fibrillation taking vitamin K antagonists 28722795 2017 07 19 2017 07 19 1742-1241 2017 Jul 19 International journal of clinical practice Int. J. Clin. Pract. Influence of renal function on anticoagulation control in patients with non-valvular atrial fibrillation taking vitamin K antagonists. 10.1111/ijcp.12974 Chronic kidney disease (CKD) has been related to poor anticoagulation control and an increased (...) risk of bleeding. This study aims to evaluate the association between impaired renal function (eGFR <60 mL/min/1.73 m(2) ) and anticoagulation control in patients with non-valvular atrial fibrillation (AF) on vitamin K antagonists (VKA) therapy. We also assessed whether the predictive value of the SAMe-TT2 R2 score prevailed for subgroups both with and without CKD. This is an ancillary analysis of 1381 patients from the PAULA study, which was a cross-sectional, retrospective and nationwide

EvidenceUpdates2017 Full Text: Link to full Text with Trip Pro

133. Notification of international normalized ratio test in atrial fibrillation patients treated with warfarin via short message service: Study protocol for a randomized controlled trial

Notification of international normalized ratio test in atrial fibrillation patients treated with warfarin via short message service: Study protocol for a randomized controlled trial 28894528 2018 11 13 2008-5842 9 7 2017 Jul Electronic physician Electron Physician Notification of international normalized ratio test in atrial fibrillation patients treated with warfarin via short message service: Study protocol for a randomized controlled trial. 4732-4736 10.19082/4732 Atrial Fibrillation (AF) is (...) the most common abnormal heart rhythm. AF patients usually use warfarin therapy. Safety and efficacy of warfarin are dependent on maintaining the International Normalized Ratio (INR) within the therapeutic range. We will use a Short Message Service (SMS) to evaluate the effect of a reminder on carrying out the INR laboratory test in a timely manner. This study (a Randomized Controlled Trial) will be done in Loghman hospital Tehran, Iran. Convenience sampling will be done and 400 AF patients that have

Electronic physician2017 Full Text: Link to full Text with Trip Pro

134. [Cryoablation for the treatment of persistent or symptomatic paroxysmal atrial fibrillation]

[Cryoablation for the treatment of persistent or symptomatic paroxysmal atrial fibrillation] [Cryoablation for the treatment of persistent or symptomatic paroxysmal atrial fibrillation] [Cryoablation for the treatment of persistent or symptomatic paroxysmal atrial fibrillation] Hernández-Vásquez A, Alcaraz A, Pichon-Riviere A, Augustovski F, García Martí S, Bardach A, Ciapponi A, López A, Rey-Ares L Record Status This is a bibliographic record of a published health technology assessment from (...) a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Hernández-Vásquez A, Alcaraz A, Pichon-Riviere A, Augustovski F, García Martí S, Bardach A, Ciapponi A, López A, Rey-Ares L. [Cryoablation for the treatment of persistent or symptomatic paroxysmal atrial fibrillation] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Documentos de Evaluación de Tecnologías Sanitarias, Informe de Respuesta Rapida No 517. 2017

Health Technology Assessment (HTA) Database.2017

135. Randomized clinical trial of landiolol hydrochloride for the prevention of atrial fibrillation and postoperative complications after oesophagectomy for cancer

Randomized clinical trial of landiolol hydrochloride for the prevention of atrial fibrillation and postoperative complications after oesophagectomy for cancer 28444964 2017 04 26 2017 06 13 1365-2168 104 8 2017 Jul The British journal of surgery Br J Surg Randomized clinical trial of landiolol hydrochloride for the prevention of atrial fibrillation and postoperative complications after oesophagectomy for cancer. 1003-1009 10.1002/bjs.10548 Atrial fibrillation is common after oesophageal surgery (...) . The aim of this study was to evaluate whether landiolol hydrochloride was effective and safe in the prevention of atrial fibrillation after oesophagectomy, and to see whether a reduction in incidence of atrial fibrillation would reduce other postoperative complications. This single-centre study enrolled patients scheduled for transthoracic oesophagectomy in a randomized, double-blind, placebo-controlled trial between March 2013 and January 2016. Enrolled patients were randomized with a 1 : 1 parallel

EvidenceUpdates2017

136. Atrial fibrillation following therapy with high-dose i.v. methylprednisolone: A brief case-based review

Atrial fibrillation following therapy with high-dose i.v. methylprednisolone: A brief case-based review 28983416 2018 11 13 2147-9720 4 3 2017 Sep European journal of rheumatology Eur J Rheumatol Atrial fibrillation following therapy with high-dose i.v. methylprednisolone: A brief case-based review. 231-233 10.5152/eurjrheum.2017.16120 Atrial fibrillation following high-dose i.v. steroids for treatment of severe immune-mediated diseases has been rarely reported in the literature. Here we report (...) a further case of atrial fibrillation following high-dose i.v. methylprednisolone (HDIVMP) therapy of severe thrombocytopenia in a female patient with a flare-up of systemic lupus erythematosus (SLE). The available literature on this topic is reviewed as well. Romano Ciro C Division of Internal Medicine, Department of Medical and Surgical Sciences, Luigi Vanvitelli University of Campania School of Medicine, Naples, Italy. Sirotti Valentina V Division of Internal Medicine, Department of Medical

European journal of rheumatology2017 Full Text: Link to full Text with Trip Pro

137. Screening strategies for atrial fibrillation: a systematic review and cost-effectiveness analysis

Screening strategies for atrial fibrillation: a systematic review and cost-effectiveness analysis Screening strategies for atrial fibrillation: a systematic review and cost-effectiveness analysis Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue (...) {{metadata .Issue }} Toolkit 1)"> 0)"> {{metadata.Title}} {{metadata.Headline}} A national screening programme for atrial fibrillation is likely to represent a cost-effective use of resources, with systematic opportunistic screening more likely to be cost-effective than systematic population screening {{author}} {{($index , , , , , , , , , , , , , , & . Nicky J Welton, 1 ,* Alexandra McAleenan, 1 Howard HZ Thom, 1 Philippa Davies, 1 Will Hollingworth, 1 Julian PT Higgins, 1 George Okoli, 1 Jonathan AC

NIHR HTA programme2017

138. CHA2DS2-VASc Score (Congestive Heart Failure, Hypertension, Age >/=75 [Doubled], Diabetes Mellitus, Prior Stroke or Transient Ischemic Attack [Doubled], Vascular Disease, Age 65-74, Female) for Stroke in Asian Patients With Atrial Fibrillation: A Korean N

CHA2DS2-VASc Score (Congestive Heart Failure, Hypertension, Age >/=75 [Doubled], Diabetes Mellitus, Prior Stroke or Transient Ischemic Attack [Doubled], Vascular Disease, Age 65-74, Female) for Stroke in Asian Patients With Atrial Fibrillation: A Korean N 28455320 2017 04 29 2017 05 23 1524-4628 48 6 2017 Jun Stroke Stroke CHA2DS2-VASc Score (Congestive Heart Failure, Hypertension, Age ≥75 [Doubled], Diabetes Mellitus, Prior Stroke or Transient Ischemic Attack [Doubled], Vascular Disease, Age (...) 65-74, Female) for Stroke in Asian Patients With Atrial Fibrillation: A Korean Nationwide Sample Cohort Study. 1524-1530 10.1161/STROKEAHA.117.016926 The CHA2DS2-VASc stroke score (congestive heart failure, hypertension, age ≥75 (doubled), diabetes mellitus, prior stroke or transient ischemic attack (doubled), vascular disease, age 65-74, female) is used in most guidelines for risk stratification in atrial fibrillation (AF), but most data for this score have been derived in Western populations

EvidenceUpdates2017

139. Atrial fibrillation as a risk factor for cognitive decline and dementia

Atrial fibrillation as a risk factor for cognitive decline and dementia 28460139 2017 05 01 2017 05 01 1522-9645 2017 Apr 29 European heart journal Eur. Heart J. Atrial fibrillation as a risk factor for cognitive decline and dementia. 10.1093/eurheartj/ehx208 To assess whether AF is a risk factor for cognitive dysfunction we used prospective data on AF, repeat cognitive scores, and dementia incidence in adults followed over 45 to 85 years. Data are drawn from the Whitehall II study, N = 10 308 (...) at study recruitment in 1985. A battery of cognitive tests was administered four times (1997-2013) to 7428 participants (414 cases of AF), aged 45-69 years in 1997. Compared with AF-free participants, those with longer exposure to AF (5, 10, or 15 years) experienced faster cognitive decline after adjustment for sociodemographic, behavioural, and chronic diseases (P for trend = 0.01). Incident stroke or coronary heart disease individually did not explain the excess cognitive decline; however

EvidenceUpdates2017 Full Text: Link to full Text with Trip Pro

140. Practical Implementation of Anticoagulation Strategy for Patients Undergoing Cardioversion of Atrial Fibrillation

Practical Implementation of Anticoagulation Strategy for Patients Undergoing Cardioversion of Atrial Fibrillation 28835835 2018 11 13 2050-3369 6 2 2017 Jun Arrhythmia & electrophysiology review Arrhythm Electrophysiol Rev Practical Implementation of Anticoagulation Strategy for Patients Undergoing Cardioversion of Atrial Fibrillation. 50-54 10.15420/aer.2017:3:2 Anticoagulation is routinely prescribed to patients with persistent AF before cardioversion to reduce the risk of thromboembolic (...) events. As direct oral anticoagulants (DOACs) have a rapid onset of action, a consistent anticoagulant effect, if taken correctly, and do not need monitoring or dose adjustments, there is considerable interest in their use for patients with AF undergoing cardioversion. Post-hoc analyses show that DOACs are safe to use prior to and following cardioversion. In addition, two randomised controlled trials, X-VeRT and ENSURE-AF, have demonstrated the efficacy and safety of the DOACs rivaroxaban

Arrhythmia & electrophysiology review2017 Full Text: Link to full Text with Trip Pro